Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Status:
RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.